medigraphic.com

2012, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (2)

M. Steinman, 2011 Nobel for his contributions on immunity

Bonifaz LC

Language: Spanish
References: 7
Page: 123-125
PDF size: 40.52 Kb.


ABSTRACT

Ralph M. Steinman was the recipient of the 2011 Nobel Prize of Physiology and Medicine due to the discovery of dendritic cells, which have a crucial role on the onset of acquired immunity, a fundamental event in the organism’s defense. Today, dendritic cells are used in the development of vaccines and in cancer therapy. Steinman’s contributions have been fundamental in the understanding of immunity.


REFERENCES

  1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137(5): 1142-1162. Disponible en http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2139237/pdf/1142.pdf

  2. Cheong C, Choi JH, Vitale L, He LZ, Trumpfheller C, Bozzacco L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010;116(19):3828-3838. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981538/? tool=pubmed

  3. Palucka AK, Paczesny S, Dhodapkar MV, Steinman RM, Fay JW, Banchereau J Dendritic cells as melanoma vaccines. J Invest Med 2003;51(Supl 2):S385-S386.

  4. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor- derived dendritic cell vaccine. Cancer Res 2001;61(17): 6451-6458.

  5. Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, et al. Single injection of CD34+ progenitor- derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003;26(5):432-439.

  6. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002;196(12):1627-1638. Disponible en http://www.ncbi. nlm.nih.gov/pmc/articles/PMC2196060/?tool=pubmed

  7. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii SI, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004;199(6):815-824. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2212731/?tool=pubmed




2020     |     www.medigraphic.com